Literature DB >> 24549056

Attenuated familial adenomatous polyposis manifests as autosomal dominant late-onset colorectal cancer.

Abdulla Ibrahim1, Daniel R Barnes2, Jacqueline Dunlop1, Daniel Barrowdale2, Antonis C Antoniou2, Jonathan N Berg1.   

Abstract

Colorectal cancer (CRC) risk is well defined for families of patients with classical familial adenomatous polyposis (FAP). However, the risk for those with an attenuated form of FAP is less well characterised. In this study, we estimated CRC risks for carriers of a novel germline mutation in the APC gene that causes attenuated FAP (AFAP). We performed genetic testing on 53 individuals from seven AFAP families harbouring an identical APC:c.288T>A mutation. Using a modified segregation analysis, we estimated relative and absolute CRC risks for mutation carriers. Twenty-three individuals harboured the disease causing mutation. CRC occurred in 28 individuals (mean 61.7 years, range 32-80 years). The estimated CRC relative risks for mutation carriers aged 60-69 and ≥70 years were 19 (95% CI: 1.77-204.08) and 45 (95% CI: 11.32-180.10), respectively, while the absolute CRC lifetime risk for men was 94% (95% CI: 67.5-99.9%), and for women, 84% (95% CI: 50.9-99.0%). This study shows that AFAP can manifest as autosomal dominant late-onset CRC. These findings highlight a subgroup of inherited CRCs that require new criteria for identification and surveillance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24549056      PMCID: PMC4140763          DOI: 10.1038/ejhg.2014.20

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  17 in total

Review 1.  Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002).

Authors:  Stuart R Cairns; John H Scholefield; Robert J Steele; Malcolm G Dunlop; Huw J W Thomas; Gareth D Evans; Jayne A Eaden; Matthew D Rutter; Wendy P Atkin; Brian P Saunders; Anneke Lucassen; Paul Jenkins; Peter D Fairclough; Christopher R J Woodhouse
Journal:  Gut       Date:  2010-05       Impact factor: 23.059

2.  Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE.

Authors:  K Lange; D Weeks; M Boehnke
Journal:  Genet Epidemiol       Date:  1988       Impact factor: 2.135

3.  Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation.

Authors:  R J Scott; N J Froggatt; R C Trembath; D G Evans; S V Hodgson; E R Maher
Journal:  Hum Mol Genet       Date:  1996-12       Impact factor: 6.150

4.  A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.

Authors:  John Burn; D Timothy Bishop; Pamela D Chapman; Faye Elliott; Lucio Bertario; Malcolm G Dunlop; Diana Eccles; Anthony Ellis; D Gareth Evans; Riccardo Fodde; Eamonn R Maher; Gabriela Möslein; Hans F A Vasen; Julie Coaker; Robin K S Phillips; Steffen Bülow; John C Mathers
Journal:  Cancer Prev Res (Phila)       Date:  2011-05

5.  Alternatively spliced adenomatous polyposis coli (APC) gene transcripts that delete exons mutated in attenuated APC.

Authors:  W S Samowitz; A Thliveris; L N Spirio; R White
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

6.  Identification of 5 novel germline APC mutations and characterization of clinical phenotypes in Japanese patients with classical and attenuated familial adenomatous polyposis.

Authors:  Hong Tao; Kazuya Shinmura; Hidetaka Yamada; Masato Maekawa; Satoshi Osawa; Yasuhiro Takayanagi; Kazuya Okamoto; Tomohiro Terai; Hiroki Mori; Toshio Nakamura; Haruhiko Sugimura
Journal:  BMC Res Notes       Date:  2010-11-16

Review 7.  Attenuated familial adenomatous polyposis (AFAP). A review of the literature.

Authors:  Anne Lyster Knudsen; Marie Luise Bisgaard; Steffen Bülow
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

8.  Alleles of the APC gene: an attenuated form of familial polyposis.

Authors:  L Spirio; S Olschwang; J Groden; M Robertson; W Samowitz; G Joslyn; L Gelbert; A Thliveris; M Carlson; B Otterud
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

9.  Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis.

Authors:  Randall W Burt; Mark F Leppert; Martha L Slattery; Wade S Samowitz; Lisa N Spirio; Richard A Kerber; Scott K Kuwada; Deborah W Neklason; James A Disario; Elaine Lyon; J Preston Hughes; William Y Chey; Raymond L White
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

Review 10.  The genetics of hereditary colon cancer.

Authors:  Anil K Rustgi
Journal:  Genes Dev       Date:  2007-10-15       Impact factor: 11.361

View more
  5 in total

1.  Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate.

Authors:  Seth Septer; Caitlin E Lawson; Shrikant Anant; Thomas Attard
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

Review 2.  How Research on Human Progeroid and Antigeroid Syndromes Can Contribute to the Longevity Dividend Initiative.

Authors:  Fuki M Hisama; Junko Oshima; George M Martin
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

Review 3.  Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management.

Authors:  Priyanka Kanth; Jade Grimmett; Marjan Champine; Randall Burt; N Jewel Samadder
Journal:  Am J Gastroenterol       Date:  2017-08-08       Impact factor: 10.864

4.  Jejunal Cancer with WRN Mutation Identified from Next-Generation Sequencing: A Case Study and Minireview.

Authors:  Christopher Chang; Her-Shyong Shiah; Nan-Yung Hsu; Hsiu-Ying Huang; Jan-Show Chu; Yun Yen
Journal:  Case Rep Surg       Date:  2014-06-15

5.  A novel APC mutation identified in a large Chinese family with familial adenomatous polyposis and a brief literature review.

Authors:  Minghui Pang; Yijun Liu; Xiaolin Hou; Jialiang Yang; Xuelai He; Nengyi Hou; Peixi Liu; Luo Liang; Junwen Fu; Kang Wang; Zimeng Ye; Bo Gong
Journal:  Mol Med Rep       Date:  2018-06-05       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.